Business
Satellos Bioscience Inc. to Present Preliminary Preclinical Proof of Concept Data for an Additional Rare Disease at World Muscle Society Meeting
- Advancements on the Company's evaluation of potential new disease indication Toronto, Ontar...
About this update from Satellos Bioscience Inc
[{"type":"text","content":"Satellos Bioscience Inc. to Present Preliminary Preclinical Proof of Concept Data for an Additional Rare Disease at World Muscle Society Meeting- Advancements on the Company's evaluation of potential new disease indicationToronto, Ontario--(Newsfile Corp. - October 11, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) (\"Satellos\" or the \"Company\"), a drug discovery company aimed at developing therapeutics that regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, announced today that Ryan Mitchell, PhD and Director of Business Development will present preliminary preclinical proof of concept data in a second rare disease, Congenital muscular dystrophy type 1A. These data will be featured in a poster presentation at this year's World Muscle Society Congress (WMS) being held in Halifax, Nova Scotia, Canada, from October 11-15, 2022.\"We are pleased to be presenting preliminary findings surrounding the preclinical treatment of a rare congenital muscular dystrophy with no known cure that is genetically distinct from our lead indication, Duchenne,\" said Frank Gleeson, MBA, Co-Founder, and Chief Executive Officer of Satellos. \"One of our stated milestones this year was the evaluation of a disease expansion indication, and we are pleased to have met this goal. We can think of no better event to showcase these preliminary findings than at the prestigious World Muscle Society Meeting.\"The Poster will be available for viewing throughout the conference and well be presented at the date and time listed below:Title: Stimulation of regeneration by targeting stem cell polarity ameliorates Muscular DystrophyDate and Time: Friday October 14th 5-6pm(ADT)A copy of the poster presentation will also be added to the events section of the Satellos website following the presentation at www.Satellos.com.About Satellos Bioscience Inc.Satellos is a biotechnology company dedicated to developing life-changing medicines to treat degenerative muscle conditions. Our scientists discovered what we believe to be a previously unrecognized root cause of skeletal muscle degeneration. One which has the potential to transform how muscle disorders are treated. Our scientific founder, Dr. Michael Rudnicki, is a thought leader who discovered and has shown how muscle stem cells regulate muscle repair and growth throughout ...